OmniAb (OABI) Operating Income (2021 - 2026)
OmniAb (OABI) posted quarterly Operating Income of -$7.8 million for Q1 2026, up 58.45% year-over-year from -$4.9 million in Q1 2025, and up 50.34% quarter-over-quarter from -$15.8 million in Q4 2025.
Powered by 
Analysis
OmniAb (OABI) Operating Income (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Operating Income for 6 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 58.45% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$58.0 million (up 18.14% YoY), while the FY2025 annual figure was -$69.0 million, up 7.43% from the prior year.
- Operating Income improved to -$7.8 million in Q1 2026 per OABI's latest filing, from -$15.8 million in the prior quarter.
- Across five years, Operating Income topped out at $9.0 million in Q4 2022 and bottomed at -$22.6 million in Q1 2024.
- Historically, Operating Income has averaged -$14.6 million across 5 years, with a median of -$16.2 million in 2025.
- On a YoY basis, Operating Income climbed as much as 125.54% in 2022 and fell as far as 575002.97% in 2022.
- OmniAb's Operating Income stood at $9.0 million in 2022, then sank by 334.32% to -$21.2 million in 2023, then grew by 25.12% to -$15.9 million in 2024, then climbed by 0.72% to -$15.8 million in 2025, then surged by 50.34% to -$7.8 million in 2026.
- Business Quant data shows OABI's Operating Income at -$7.8 million in Q1 2026, -$15.8 million in Q4 2025, and -$18.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -1.55 Mn |
| 10 | OmniAb | 582.15 Mn | 530.16 Mn | 12.81 Mn | -6.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.64 Mn |
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -16.22 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | -15.88 Mn |
| Sep 30, 2024 | -19.76 Mn |
| Jun 30, 2024 | -16.31 Mn |
| Mar 31, 2024 | -22.55 Mn |
| Dec 31, 2023 | -21.21 Mn |
| Sep 30, 2023 | -20.32 Mn |
| Jun 30, 2023 | -19.45 Mn |
| Mar 31, 2023 | -8.45 Mn |
| Dec 31, 2022 | 9.05 Mn |
| Sep 30, 2022 | -14.91 Mn |
| Jun 30, 2022 | -12.57 Mn |
| Mar 31, 2022 | -8.22 Mn |
| Dec 31, 2021 | -35.43 Mn |
| Sep 30, 2021 | -170,579.00 |